Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Albireo Pharma Inc
(NQ:
ALBO
)
34.86
USD
-0.22 (-0.63%)
Streaming Delayed Price
Updated: 4:04 PM EST, Feb 26, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Albireo Pharma Inc
< Previous
1
2
3
4
5
Next >
Albireo Spotlights Global Patient Communities on Rare Disease Day
Today 8:30 EST
From
GlobeNewswire News Releases
Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update
February 25, 2021
From
GlobeNewswire News Releases
Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
February 23, 2021
From
GlobeNewswire News Releases
Albireo to Report Q4 and Year-End 2020 Financial Results on February 25
February 18, 2021
Conference call and webcast to be held at 10:00 a.m. ET
From
GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 17, 2021
From
GlobeNewswire News Releases
Albireo Presents Odevixibat Commercialization Road to $1 Billion
February 11, 2021
From
GlobeNewswire News Releases
Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat
January 25, 2021
From
GlobeNewswire News Releases
Albireo Recognizes International Alagille Syndrome Awareness Day 2021
January 22, 2021
Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases
From
GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 14, 2021
From
GlobeNewswire News Releases
Albireo to Host Virtual Investor Commercial Day 2021
January 07, 2021
From
GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 06, 2021
From
GlobeNewswire News Releases
Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences
January 05, 2021
From
GlobeNewswire News Releases
Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome
December 17, 2020
From
GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 11, 2020
From
GlobeNewswire News Releases
Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC
December 08, 2020
From
GlobeNewswire News Releases
New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease
November 13, 2020
From
GlobeNewswire News Releases
Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences
November 12, 2020
From
GlobeNewswire News Releases
Albireo Reports Q3 2020 Financial Results and Provides Business Update
November 05, 2020
From
GlobeNewswire News Releases
Albireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers
November 02, 2020
From
GlobeNewswire News Releases
Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting
October 23, 2020
From
GlobeNewswire News Releases
Albireo Recognizes PFIC Awareness Day 2020
October 05, 2020
Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases
From
GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2020
From
GlobeNewswire News Releases
Albireo Prices Public Offering of 4,000,000 Shares of Common Stock
September 09, 2020
From
GlobeNewswire News Releases
Albireo Announces Proposed Public Offering of 3,000,000 Shares of Common Stock
September 08, 2020
From
GlobeNewswire News Releases
Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC
September 08, 2020
From
GlobeNewswire News Releases
Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020
September 07, 2020
— Conference call and webcast to be held at 8:30 a.m. EDT —
From
GlobeNewswire News Releases
Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH
August 18, 2020
From
GlobeNewswire News Releases
Albireo Reports Q2 2020 Financial Results and Provides Business Update
August 06, 2020
From
GlobeNewswire News Releases
Albireo to Present at the William Blair Biotech Focus Conference 2020
July 30, 2020
From
GlobeNewswire News Releases
Albireo to Report Q2 2020 Financial Results on August 6
July 30, 2020
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.